Kite Pharma, Inc. (KITE)

Oncology Corporate Profile

Stock Performance

78.2600
0.0000

HQ Location

2225 Colorado Avenue
Santa Monica, CA 90404

Company Description

Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapeutic products, with a major focus on eACT therapy designed at restoring the patient's immune system to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments.

Website: http://www.kitepharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
axicabtagene ciloleucelchimeric antigen receptor (CAR)_Diffuse large B-cell Lymphoma (DLBCL)II
axicabtagene ciloleucelchimeric antigen receptor (CAR)_Primary mediastinal b-cell Lymphoma (PMBCL)II
axicabtagene ciloleucelchimeric antigen receptor (CAR)_Transformed follicular Lymphoma (TFL)II
KTE-C19chimeric antigen receptorAcute Lymphoblastic LeukemiaI
KTE-C19chimeric antigen receptorB-cell LymphomaI
HPV-16 E6 & E7t-cell therapyCervical cancerINCI
KTE-C19chimeric antigen receptorDiffuse large B-cell Lymphoma (DLBCL)I
EGFRvIII CARchimeric antigen receptorGlioblastoma Multiforme (GBM)I
HPV-16 E6 & E7t-cell therapyHead & Neck cancerINCI
KTE-C19chimeric antigen receptorMantle Cell Lymphoma (MCL)II
KTE-C19chimeric antigen receptor2nd line Diffuse large B-cell Lymphoma (DLBCL)Preclinical
KTE-C19chimeric antigen receptorAcute Myelogenous Leukemia (AML)Preclinical
KTE-C19chimeric antigen receptorChronic Lymphocytic Leukemia (CLL)Preclinical
KTE-C19chimeric antigen receptorNon-Hodgkin's Lymphoma (NHL)Preclinical
eACTt-cell therapyVarious cancer typesPreclinical

View additional information on product candidates here »

Source


http://www.kitepharma.com

Recent News Headlines

Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors

3/16/2017 12:03 pm

[Business Wire] - Kite Pharma, Inc. today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles and a renowned cancer researcher, has been appointed to its Board of Directors.

Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell

3/14/2017 08:01 pm

[Business Wire] - Kite Pharma, Inc. today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute study of anti-CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma .

KITE PHARMA, INC. Financials

3/10/2017 06:00 pm

Kite Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

3/8/2017 01:03 pm

[Business Wire] - Kite Pharma, Inc. today announced the closing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $75.00 per share, as well as the exercise in full of the underwriters’ option to purchase 712,500 additional shares.

Kite to Present at March 2017 Investor Conferences

3/6/2017 01:03 pm

[Business Wire] - Kite Pharma, Inc. today announced that management will present at two investor conferences in March 2017:

Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead Development of Axicabtagene Ciloleucel and Other Engineered T-Cell Therapies for Treatment of Cancers in China

3/5/2017 09:00 pm

[Business Wire] - Kite Pharma, Inc., today announced that Richard L. Wang, Ph.D. will be appointed Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd, the company’s 50/50 owned joint venture in China with Shanghai Fosun Pharmaceutical Co., Ltd.